Allan Hillary Steinhart

Dr. Allan Hillary Steinhart

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
Eran ZittanEran Zittan
Eran Zittan
ASAllan Hillary Steinhart
Allan Hillary Steinhart
PGPavel Goldstein
Pavel Goldstein
RMRaquel Milgrom
Raquel Milgrom
IGIan M. Gralnek
Ian M. Gralnek
MSMark S. Silverberg
Mark S. Silverberg
INTRODUCTION: We investigated whether early adalimumab drug levels (ADL) at week 4 predicted biological remission at week 24. METHODS: In a prospective study, we assessed clinical and biological remission at weeks 0, 4, 12, and 24 after induction of adalimumab in 33 patients with Crohn's disease. Disease activity was determined by the Harvey-Bradshaw Index, ileocolonoscopy reports, cross-sectional imaging, C-reactive protein (CRP), and fecal calprotectin (FC) levels. Clinical remission was defined as Harvey-Bradshaw Index <5. Biological remission was defined as a combination of FC < 200 μg/g and CRP 13.9 μg/mL) were significantly associated with biological remission at week 24.

4 September 2023 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
PDF file
RDRonit Das
Ronit Das
ASAllan Hillary Steinhart
Allan Hillary Steinhart
Those managing ulcerative colitis (UC) must be aware of new treatments. Mesalamine (5-ASA) is the first treatment for mild UC. Steroids have been the first therapy for patients with more severe UC but these are not effective or safe long term. This means that other medicines are needed. Newer advanced therapies are now frequently used. There are several types of advanced therapies. These are the anti-TNF, anti-integrin and anti-IL12/23 agents as well as the JAK inhibitors and sphingosine1-phosphate receptor modulators. All of these are effective in treating UC. Choosing among treatments is complicated. There are multiple factors to think about when choosing a treatment for UC. Without research studies that directly compare the different treatments, the use of any one treatment should be based on effectiveness and safety. Other considerations include specific disease features, patient factors and the preference of patients.

26 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GFGionata Fiorino
Gionata Fiorino
AAAshwin Ananthakrishnan
Ashwin Ananthakrishnan
RCRussell D. Cohen
Russell D. Cohen
RCRaymond K. Cross
Raymond K. Cross
PDParakkal Deepak
Parakkal Deepak
ASAllan Hillary Steinhart
Allan Hillary Steinhart
Data indicate that earlier initiation of anti-tumor necrosis factor alpha (anti-TNF-α) biologic medicines may prevent progression to irreversible bowel damage and improve outcomes for patients with inflammatory bowel disease (IBD), particularly Crohn’s disease. However, the high cost of such therapies may restrict access and prevent timely treatment of IBD. Biosimilar anti-TNF-α medicines may represent a valuable opportunity for cost savings and optimized patient outcomes by improving access to advanced therapies and allowing earlier anti-TNF-α treatment initiation. Biosimilar anti-TNF-α medicines have been shown to offer consistent therapeutic outcomes to their reference medicines, yet despite entering the IBD treatment armamentarium over 10 years ago, their implementation in clinical practice remains suboptimal. Factors limiting the ‘real’ use of biosimilar anti-TNF-α medicines may include an ongoing lack of understanding and acceptance of biosimilars by both healthcare professionals (HCPs) and patients, as well as systemic factors such as formulary decisions outside of the control of the prescriber. In this review, an expert panel of gastroenterologists discusses HCP-level considerations to improve biosimilar anti-TNF-α utilization in IBD in order to support early anti-TNF-α initiation and maximize patient outcomes.

1 January 2025 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
DSDavid C. Sealey
David C. Sealey
KHKai Fai Ho
Kai Fai Ho
ZZZ. Christina Zhou
Z. Christina Zhou
MCMichael Clark
Michael Clark
BFBrian G. Feagan
Brian G. Feagan
WAWaqqas Afif
Waqqas Afif
Background: Although it is generally believed that infliximab dose optimization in patients with inflammatory bowel disease with low serum infliximab concentration at trough results in increased treatment persistence, empirical data to support this notion are lacking. This study evaluated the association of infliximab therapeutic drug monitoring (TDM) and TDM‐associated dose optimization with persistence in real‐world practice. Methods: Data from adults with Crohn’s disease (CD) or ulcerative colitis (UC) who participated in a national patient support program (PSP) in Canada were analyzed. Participants who had a first TDM evaluation (with a recorded infliximab trough concentration) in the maintenance phase of treatment were assessed (excluding those who underwent prior dose optimization). Persistence was evaluated using time‐dependent Cox proportional hazards models. Results: In the overall population of patients with CD or UC, TDM was not associated with longer persistence ( n = 13,203). In patients with no prior dose optimization ( n = 2729) who had a serum infliximab concentration of < 3 μg/mL, dose optimization within 9 weeks of TDM was associated with significantly longer persistence (HR: 0.36; 95% CI: 0.26, 0.50 for CD [ n = 711] and HR: 0.30, 95% CI: 0.21, 0.43 for UC [ n = 501]). Sensitivity analyses yielded similar results when using a threshold concentration of < 5 μg/mL. In an analysis excluding patients who received no further treatment after TDM, the association between dose optimization and longer persistence was not confirmed in patients with CD, and mostly confirmed in patients with UC at a threshold concentration of < 3 μg/mL. Conclusion: TDM‐associated dose optimization in patients with UC with low serum infliximab concentrations was associated with longer persistence. This association was not confirmed in patients with CD. This study demonstrated that real‐world data from a PSP‐generated cohort can be evaluated to inform clinical practice and that this approach may be complementary to other types of cohort studies.

7 August 2025 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
Eran ZittanEran Zittan
Eran Zittan
MLMatthew Levy
Matthew Levy
SVShiraz Vered
Shiraz Vered
ASAllan Hillary Steinhart
Allan Hillary Steinhart
RMRaquel Milgrom
Raquel Milgrom
SZShira Zelber-Sagi
Shira Zelber-Sagi
INTRODUCTION: The Toronto Inflammatory Bowel Disease (IBD) Global Endoscopic Reporting (TIGER) score was developed to provide 1 endoscopic scoring index for patients with both Crohn's disease (CD) and ulcerative colitis (UC). The goal of this study was to assess the predictive validity the TIGER score for daily-life disease burden (IBD Disk) and disease complications. METHODS: A prospective 12-month study was conducted in 1 tertiary IBD center. Baseline colonoscopy was performed. Moderate-to-severe mucosal involvement was defined as a TIGER score ≥100, Simple Endoscopic Score for CD >6, Mayo Endoscopic Score >1, and was used as a predictor for clinical outcomes. At each visit, IBD Disk questionnaires, disease complications, hospitalizations, surgeries, and medications were documented. RESULTS: A total of 107 adults, 52 with CD and 55 with UC, were included. Patients with a baseline TIGER score ≥100 had a significantly higher prevalence of an IBD Disk score ≥40 after the 12-month follow-up period despite receiving advanced therapy (33.9% vs 7.8%, P < 0.001). There were significantly more patients with a baseline TIGER score ≥100 who experienced at least 1 hospitalization (39.3% vs 2.0%, P < 0.001), underwent surgery (14.3% vs 0.0%, P < 0.005), had IBD-related complications (41.1% vs 9.8%, P < 0.001), and required steroids (67.9% vs 5.9%, P < 0.001) or advanced therapy (85.7% vs 7.8%, P < 0.001). Similar significant results were obtained with Simple Endoscopic Score for CD and Mayo Endoscopic Score as predictors of outcomes over the 12 months. DISCUSSION: The TIGER score is a simple endoscopic score for patients with CD and UC with an adequate predictive validity for worse clinical outcomes while having noninferiority to the current best-referenced endoscopic scores.

27 May 2026 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
HLHaim Leibovitzh
Haim Leibovitzh
ANAnna Neustaeter
Anna Neustaeter
SLSun-Ho Lee
Sun-Ho Lee
MXMingyue Xue
Mingyue Xue
OEOsvaldo Espin-Garcia
Osvaldo Espin-Garcia
KCKenneth Croitoru
Kenneth Croitoru
Single nucleotide polymorphisms (SNPs) in the Interleukin-23 receptor (IL23-R) gene are associated with Crohn's disease (CD), suggesting a role in pathogenesis and several biologic agents targeting this pathway are now established therapies. IL-23 has been suggested to be involved in regulation of intestinal barrier function and may impact gut microbial composition. We investigated whether IL23-R genetic variants predict CD risk and influence gut barrier function and microbiome composition in healthy first-degree relatives (FDRs). 3,055 healthy FDRs with genotypic data from the Genetic Environmental Microbial (CCC-GEM) cohort were included. A weighted IL23R genetic risk score (IL23R-GRS) was generated from seven CD-associated IL23R SNPs and dichotomized as High (top quintile) vs. Low IL23R-GRS. A subset of this cohort was assessed for intestinal permeability (n=1,698) and microbiome profiling (n=2,523). Cox proportional-hazards models evaluated CD onset risk. High IL23R-GRS was associated with increased CD risk (hazard ratio 1.67, 95% confidence interval 1.01-2.75, p=0.044). This association remained significant after adjusting for fecal calprotectin, indicating genetic risk independent of subclinical inflammation. High IL23R-GRS was not associated with intestinal permeability (p=0.84) but was associated with differences in 15 genera, including decreased Faecalibacterium and increased Akkermansia (q<0.1). High IL23R-GRS was associated with increased CD risk in healthy FDRs and was associated with microbial differences, but not with intestinal permeability. These findings suggest potential clinical applications for IL23R-GRS in identifying high-risk individuals who may benefit from closer monitoring or future IL-23 pathway-targeted preventive interventions.